viewMotif Bio PLC

Motif Bio PLC calls time on iclaprim


Motif is confident there is a path to market for iclaprim, it will require a company with deeper pockets to take the putative treatment further.


Quick facts: Motif Bio PLC

Price: 0.1415 GBX

Market: AIM
Market Cap: £686.77 k
  • Motif Bio is to sell antibiotic iclaprim after FDA setback 

  • US regulator requested new trial after concerns over toxicity

  • Company will wind down US business


What next?

Motif says a new trial for iclaprim will cost tens of millions of dollars.

Instead, it is proposing to sell iclaprim, its main asset, as part of a root and branch reorganisation of the company.

The drug developer had been talking with the US regulator following queries over its phase III clinical trial.

Minutes of a Type B meeting between Motif and  Food and Drug Administration in September have been published.

They reveal a single well-designed adequate and well-controlled Phase III clinical trial demonstrating safety and efficacy of iclaprim in patients with bacterial pneumonia (HABP/VABP), along with data on potential mechanisms of hepatic injury, would enable submission of a New Drug Application.

And while Motif is confident there is a path to market for iclaprim, it will require a company with deeper pockets to take the putative treatment further.

“It would take several years to enrol and complete a HABP/VABP phase III trial and the cost is expected to be tens of millions of dollars,” said CEO Graham Lumsden.

“We believe that the most efficient way to generate future value from iclaprim is for a partner or other entity with a lower cost of capital to complete the HABP/VABP Phase III trial and commercialise the asset globally.”



Shortly after Motif announced the plans for iclaprim, it conditionally raised £600,000 to facilitate the restructuring.

Shareholders will also be asked to grant secured lender Hercules Capital a warrant over 20% of the group’s share capital following the placing and to reorganise the company’s share capital.

Placing shares were priced at 0.42p.

Market price at the time was 0.68p, which values the business at £2.1mln.


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Motif Bio PLC named herein, including the promotion by the Company of Motif Bio PLC in any Content on the Site, the Company receives from said...



Motif Bio's Graham Lumsden updates on FDA discussions and iclaprim potential

Motif Bio PLC's (LON:MTFB) Graham Lumsden chats to Proactive London's Andrew Scott after a meeting earlier this month with Food and Drug Administration officials to chart the next steps to get US regulators to approve their antibiotic iclaprim. Feedback from that meeting is expected in...

on 24/5/19

2 min read